Europe follows FDA to get nod for early stage Alzheimer's therapies
London
EUROPEAN regulators are following in the footsteps of the US Food and Drug Administration (FDA) with plans to help pharmaceutical companies win approval for novel Alzheimer's drugs that treat the earliest stages of the memory-robbing disease.
The European Medicines Agency said on Wednesday that its new guidance would encourage the testing of new medicines even before symptoms appeared, as well as the potential use of biomarkers, such as signs of protein build-up in the brain.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Starbucks points to weaker consumer as profit falls
Restaurant Brands tops estimates as Burger King overhaul pays off
Walmart to shut all health centers in US over lack of profitability
Coca-Cola raises annual sales forecast on global demand, higher prices
Dying salmon trouble Norway’s vast fish-farm industry
Fast-fashion giant Shein wants to sell skincare, toothpaste and toys, too